{
    "name": "tivozanib",
    "comment": "Rx",
    "other_names": [
        "Fotivda"
    ],
    "classes": [
        "Antineoplastics",
        "VEGF Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/fotivda-tivozanib-1000170",
    "pregnancy": {
        "common": [
            "No data are available on use",
            "Verify pregnancy status of females of reproductive potential before starting treatment"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Oral administration of tivozanib to pregnant animals during organogenesis caused maternal toxicity, fetal malformations and embryofetal death at doses below the maximum recommended clinical dose on a mg/m",
                    " basis"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for 1 month after last dose",
                    "Males with female partners of reproductive potential: Use effective contraception during treatment and for 1 month after last dose"
                ]
            },
            {
                "type": "Fertility",
                "description": [
                    "Females and males of reproductive potential: Can impair fertility"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence in human milk, effects on the breastfed children, or on milk production",
            "Advise not to breastfeed during treatment and for 1 month after last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "May cause fetal harm",
                "Imprint ink on 0.89-mg capsule contains FD&C yellow No.5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible patients; sensitivity is commonly seen in patients who also have aspirin hypersensitivity",
                "RPLS can occur; evaluate for RPLS in any patient presenting with seizures, headaches, visual disturbances, confusion, or altered mental function",
                "May cause thyroid dysfunction; monitor thyroid function before initiation of, and periodically throughout, treatment; treat hypothyroidism and hyperthyroidism to maintain euthyroid state before and during treatment",
                "Can cause serious, sometimes fatal, cardiac ischemia and arterial thromboembolic events; not studied in patients with significant bleeding or who have had an arterial thrombotic event, myocardial infarction, or unstable angina within the preceding 6 months before initiating",
                "Proteinuria reported; monitor for proteinuria before initiating, and periodically during treatment; discontinue if nephrotic syndrome develops"
            ],
            "specific": [
                {
                    "type": "Hypertension and hypertensive crisis",
                    "description": [
                        "May cause severe hypertension and hypertensive crisis",
                        "Median time to onset of hypertension was 2 weeks",
                        "Not studied in patients with systolic blood pressure (BP) >150 mmHg or diastolic BP >100 mmHg",
                        "Control BP before treatment",
                        "Monitor BP after 2 weeks and at least monthly thereafter during treatment",
                        "Treat with antihypertensive therapy when hypertension occurs",
                        "If therapy interrupted, monitor patients receiving antihypertensive medications for hypotension"
                    ]
                },
                {
                    "type": "Cardiac failure",
                    "description": [
                        "Serious, sometimes fatal, cardiac failure may occur",
                        "Not studied in patients with symptomatic cardiac failure within the preceding 6 months before initiating",
                        "Periodically monitor for symptoms of cardiac failure throughout treatment"
                    ]
                },
                {
                    "type": "Risk of impaired wound healing ",
                    "description": [
                        "Impaired wound healing can occur in patients who receive drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway, such as tivozanib",
                        "May adversely affect wound healing",
                        "Withhold for at least 24 days prior to elective surgery",
                        "Do not administer for at least 2 weeks following major surgery and until adequate wound healing",
                        "Safety of resumption after resolution of wound healing complications has not been established"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "CYP3A4 substrate; inhibits BCRP",
                        "Strong CYP3A4 inducers",
                        "Avoid coadministration",
                        "Strong CYP3A4 inducers may decrease exposure and efficacy of tivozanib"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bosentan",
            "description": {
                "common": "bosentan will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "dabrafenib will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etravirine",
            "description": {
                "common": "etravirine will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "ivosidenib will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lumacaftor/ivacaftor",
            "description": {
                "common": "lumacaftor/ivacaftor will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nafcillin",
            "description": {
                "common": "nafcillin will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of tivozanib by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hr before, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital will decrease the level or effect of tivozanib by  affecting hepatic enzyme CYP2E1 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "armodafinil",
            "description": {
                "common": "armodafinil will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bexarotene",
            "description": {
                "common": "bexarotene will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brigatinib",
            "description": {
                "common": "brigatinib will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clobazam",
            "description": {
                "common": "clobazam will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elagolix",
            "description": {
                "common": "elagolix will increase the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eslicarbazepine acetate",
            "description": {
                "common": "eslicarbazepine acetate will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorlatinib",
            "description": {
                "common": "lorlatinib will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "pexidartinib will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod and tivozanib both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and tivozanib both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telotristat ethyl",
            "description": {
                "common": "telotristat ethyl will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Fatigue",
            "percent": "67"
        },
        {
            "name": "Creatinine increased",
            "percent": "50"
        },
        {
            "name": "Glucose increased",
            "percent": "50"
        },
        {
            "name": "Hypertension",
            "percent": "44"
        },
        {
            "name": "Diarrhea",
            "percent": "43"
        },
        {
            "name": "Decreased appetite",
            "percent": "39"
        },
        {
            "name": "Phosphate decreased",
            "percent": "38"
        },
        {
            "name": "Sodium decreased",
            "percent": "36"
        },
        {
            "name": "Lipase increased",
            "percent": "32"
        },
        {
            "name": "ALT increased",
            "percent": "30"
        },
        {
            "name": "Alkaline phosphatase increased",
            "percent": "30"
        },
        {
            "name": "Nausea",
            "percent": "30"
        },
        {
            "name": "AST increased",
            "percent": "28"
        },
        {
            "name": "Dysphonia",
            "percent": "27"
        },
        {
            "name": "aPTT prolonged",
            "percent": "26"
        },
        {
            "name": "Potassium increased",
            "percent": "26"
        },
        {
            "name": "Magnesium decreased",
            "percent": "26"
        },
        {
            "name": "Lymphocytes decreased",
            "percent": "25"
        },
        {
            "name": "Hypothyroidism",
            "percent": "24"
        },
        {
            "name": "Amylase increased",
            "percent": "23"
        },
        {
            "name": "Cough",
            "percent": "22"
        },
        {
            "name": "Stomatitis",
            "percent": "21"
        },
        {
            "name": "Hemoglobin increased",
            "percent": "19"
        },
        {
            "name": "Platelets decreased",
            "percent": "19"
        },
        {
            "name": "Back pain",
            "percent": "19"
        },
        {
            "name": "Rash",
            "percent": "18"
        },
        {
            "name": "Vomiting",
            "percent": "18"
        },
        {
            "name": "Bleeding",
            "percent": "17"
        },
        {
            "name": "Weight decreased",
            "percent": "17"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "16"
        },
        {
            "name": "Palmoplantar erythrodysesthesia syndrome",
            "percent": "16"
        },
        {
            "name": "Calcium increased",
            "percent": "15"
        },
        {
            "name": "Dyspnea",
            "percent": "15"
        },
        {
            "name": "Proteinuria",
            "percent": "15"
        },
        {
            "name": "Venous thromboembolism",
            "percent": "15"
        },
        {
            "name": "Arterial thromboembolism",
            "percent": "15"
        },
        {
            "name": "Hyperthyroidism",
            "percent": "15"
        },
        {
            "name": "Hepatobiliary disorders",
            "percent": "15"
        },
        {
            "name": "Osteonecrosis",
            "percent": "15"
        },
        {
            "name": "Cardiac failure",
            "percent": "15"
        },
        {
            "name": "Delirium",
            "percent": "15"
        },
        {
            "name": "Bilirubin increased",
            "percent": "11"
        },
        {
            "name": "Hypertension",
            "percent": "24"
        },
        {
            "name": "Fatigue",
            "percent": "13"
        },
        {
            "name": "Sodium decreased",
            "percent": "9"
        },
        {
            "name": "Lipase increased",
            "percent": "9"
        },
        {
            "name": "Phosphate decreased",
            "percent": "5"
        },
        {
            "name": "Lymphocytes decreased",
            "percent": "5"
        },
        {
            "name": "Decreased appetite",
            "percent": "5"
        },
        {
            "name": "ALT increased",
            "percent": "4"
        },
        {
            "name": "Alkaline phosphatase increased",
            "percent": "4"
        },
        {
            "name": "Glucose increased",
            "percent": "3"
        },
        {
            "name": "Potassium increased",
            "percent": "3"
        },
        {
            "name": "Bilirubin increased",
            "percent": "3"
        },
        {
            "name": "Bleeding",
            "percent": "3"
        },
        {
            "name": "Dyspnea",
            "percent": "3"
        },
        {
            "name": "Decreased weight",
            "percent": "3"
        },
        {
            "name": "Amylase increased",
            "percent": "2"
        },
        {
            "name": "Calcium increased",
            "percent": "2"
        },
        {
            "name": "Diarrhea",
            "percent": "2"
        },
        {
            "name": "Stomatitis",
            "percent": "2"
        },
        {
            "name": "Back pain",
            "percent": "2"
        },
        {
            "name": "aPTT prolonged",
            "percent": "1"
        },
        {
            "name": "AST increased",
            "percent": "1"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "1"
        },
        {
            "name": "Vomiting",
            "percent": "1"
        },
        {
            "name": "Dysphonia",
            "percent": "1"
        },
        {
            "name": "Hypothyroidism",
            "percent": "1"
        },
        {
            "name": "Rash",
            "percent": "1"
        },
        {
            "name": "Palmoplantar erythrodysesthesia syndrome",
            "percent": "1"
        }
    ]
}